The iron chelator, Desferal, suppressed disease activity of experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), and it has been tested in pilot trials for MS. The administration regimen of Desferal is cumbersome and prone to complications. Orally-deliverable, iron chelators have been developed that circumvent these difficulties, and the objective of this study was to test an oral chelator in EAE. SJL mice with active EAE were randomly assigned to receive deferiprone (150 mg/kg) or vehicle (water) 2×/day via gavage. EAE mice given deferiprone had significantly less disease activity and lower levels of inflammatory cell infiltrates (revealed by H&E staining) than EAE mice administered vehicle. T-cell infiltration, assessed by anti-CD3 immunohistochemical staining, also was reduced, although not significantly. Splenocytes cultured from naïve SJL mice were stimulated with anti-CD3 and anti-CD28 with or without 250 μM deferiprone. While ~39% of costimulated splenocytes without deferiprone underwent division, only ~2.8% of costimulated splenocytes with deferiprone divided and the latter cells were only 53% as viable as the former. Deferiprone had no effect on proliferation or viability of cells that were not costimulated. In summary, deferiprone effectively suppressed active EAE disease and it inhibited T-cell function. Multiple Sclerosis 2007; 13: 1118—1126. http://msj.sagepub.com
Bowern N., Ramshaw IA, Clark IA, Doherty PCInhibition of autoimmune neuropathological process by treatment with an iron-chelating agent. J Exp Med1984; 160: 1532—43.
2.
Pedchenko TV , LeVine SMDesferrioxamine suppresses experimental allergic encephalomyelitis induced by MBP in SJL mice. J Neuroimmunol1998; 84: 188—97.
3.
Wu GS, Walker J., Rao NAEffect of deferoxamine on retinal lipid peroxidation in experimental uveitis . Invest Ophthalmol Vis Sci1993; 34: 3084—89.
4.
Weilbach FX, Chan A., Toyka KV, Gold R.The cardioprotector dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis. Clin Exp Immunol2004; 135: 49—55.
5.
LeVine SM, Chakrabarty A.The role of iron in the pathogenesis of experimental allergic encephalomyelitis and multiple sclerosis. Ann New York Acad Sci2004; 1012: 252—66.
6.
Forge JK, Pedchenko TV, LeVine SM. Iron deposits in the central nervous system of SJL mice with experimental allergic encephalomyelitis. Life Sci1998; 63: 2271—84.
7.
Gilgun-Sherki Y., Melamed E., Offen D.The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J Neurol2004; 251: 261—68.
8.
Sayre LM, Moreira PI, Smith MA, Perry G.Metal ions and oxidative protein modification in neurological disease. Ann Ist Super Sanita2005; 41: 143—64.
9.
Britton RS, Leicester KL, Bacon BRIron toxicity and chelation therapy. Int J Hematol2002; 76: 219—28.
10.
Rajesh M., Sulochana KN, Ramakrishnan S., Biswas J., Manoharan PTIron chelation abrogates excessive formation of hydroxyl radicals and lipid peroxidation products in monocytes of patients with Eales' disease: direct evidence using electron spin resonance spectroscopy. Curr Eye Res2004; 28: 399—407.
11.
Fisher AE, Naughton DPTherapeutic chelators for the twenty first century: new treatments for iron and copper mediated inflammatory and neurological disorders. CurrDrug Deliv2005; 2: 261—68.
12.
Terman A., Gustafsson B., Brunk UTThe lysosomalmitochondrial axis theory of postmitotic aging and cell death . Chem Biol Interact2006; 163: 29—37.
13.
Norstrand IF , Craelius W.A trial of deferoxamine (Desferal) in the treatment of multiple sclerosis: a pilot study. Clin Trials J1989; 26: 365—69.
14.
Lynch SG, Peters K., LeVine SMDesferrioxamine in chronic progressive multiple sclerosis: a pilot study. Mult Scler1996; 2: 157—60.
15.
Lynch SG, Fonseca T., LeVine SMA multiple course trial of desferrioxamine in chronic progressive multiple sclerosis. Cell Mol Biol (Noisy-le-grand)2000; 46: 865—69.
16.
Chakrabarty A., Fleming KK, Marquis JG, LeVine SMQuantifying immunohistochemical staining of phospho-eIF2alpha, heme oxygenase-2 and NADPH cytochrome P450 reductase in oligodendrocytes during experimental autoimmune encephalomyelitis. J Neurosci Methods2005; 144: 227—34.
17.
Chakrabarty A., Emerson MR, LeVine SMHeme oxygenase-1 in SJL mice with experimental allergic encephalomyelitis. Mult Scler2003 ; 9: 372—81.
18.
Chirathaworn C., Kohlmeier JE, Tibbetts SA, Rumsey LM, Chan MA, Benedict SHStimulation through intercellular adhesion molecule-1 provides a second signal for T cell activation. J Immunol2002; 168: 5530—37.
19.
Bartfay WJ, Lehotay DC, Sher GD, Bartfay E., Tyler B., Luo X. et al. Erythropoiesis: comparison of cytotoxic aldehyde generation in beta-thalassemia patients chelated with deferoxamine or deferiprone (L1) versus NO chelation. Hematology1999; 4: 67—76.
20.
Del Vecchio GC, Schettini F., Piacente L., De Santis A., Giordano P., De Mattia D.Effects of deferiprone on immune status and cytokine pattern in thalassaemia major. Acta Haematol2002; 108: 144—49.
21.
Cooper CE, Lynagh GR, Hoyes KP, Hider RC, Cammack R., Porter JBThe relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase. J Biol Chem1996; 271: 20291—99.
22.
Glickstein H. , El RB, Shvartsman M., Cabantchik ZIIntracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood2005; 106: 3242—50.
23.
Glickstein H. , El RB, Link G., Breuer W., Konijn AM, Hershko C. et al. Action of chelators in iron-loaded cardiac cells: Accessibility to intracellular labile iron and functional consequences . Blood2006; 108: 3195—203.
24.
Xu LJ, Jin L., Pan H., Zhang AZ, Wei G., Li PP et al. Deferiprone protects the isolated atria from cardiotoxicity induced by doxorubicin. Acta Pharmacol Sin2006; 27: 1333—39.
25.
Eybl V., Kotyzova D., Kolek M., Koutensky J., Nielsen P.The influence of deferiprone (L1) and deferoxamine on iron and essential element tissue level and parameters of oxidative status in dietary iron-loaded mice . Toxicol Lett2002; 128: 169—75.
26.
Morel I., Cillard J., Lescoat G., Sergent O., Pasdeloup N., Ocaktan AZ et al. Antioxidant and free radical scavenging activities of the iron chelators pyoverdin and hydroxypyrid-4-ones in iron-loaded hepatocyte cultures: comparison of their mechanism of protection with that of desferrioxamine. Free Radic Biol Med1992; 13: 499—508.
27.
Morel I., Sergent O., Cogrel P., Lescoat G., Pasdeloup N., Brissot P. et al. EPR study of antioxidant activity of the iron chelators pyoverdin and hydroxypyrid-4-one in iron-loaded hepatocyte culture: comparison with that of desferrioxamine. Free Radic Biol Med1995; 18: 303—10.
28.
Cragg L., Hebbel RP, Miller W., Solovey A., Selby S., Enright H.The iron chelator L1 potentiates oxidative DNA damage in iron-loaded liver cells. Blood1998; 92: 632—38.
29.
Marshall R. , Tricta F., Galanello R., Leoni G., Kirkland D., Minto S. et al. Chromosomal aberration frequencies in patients with thalassaemia major undergoing therapy with deferiprone and deferoxamine in a comparative crossover study. Mutagenesis2003; 18: 457—63.
30.
Carlson NG, Rose JWAntioxidants in multiple sclerosis: do they have a role in therapy? CNSDrugs2006; 20: 433—41.
LeVine SM. Iron deposits in multiple sclerosis and Alzheimer's disease brains. Brain Res1997; 760: 298—303.
33.
Drayer BP, Burger P., Hurwitz B., Dawson D., Cain J., Leong J. et al. Magnetic resonance imaging in multiple sclerosis: decreased signal in thalamus and putamen. Ann Neurol1987; 22: 546—50.
34.
Drayer B., Burger P., Hurwitz B., Dawson D., Cain J.Reduced signal intensity on MR images of thalamus and putamen in multiple sclerosis: increased iron content?AJR Am J Roentgenol1987; 149: 357—63.
35.
Grimaud J., Millar J., Thorpe JW, Moseley IF, McDonald WI, Miller DHSignal intensity on MRI of basal ganglia in multiple sclerosis. J Neurol Neurosurg Psychiatry1995; 59: 306—308.
36.
Russo C., Smoker WR, Kubal W.Cortical and subcortical T2 shortening in multiple sclerosis. AJNR Am J Neuroradiol1997; 18: 124—26.
37.
Bakshi R., Shaikh ZA, Janardhan V.MRI T2 shortening (`black T2') in multiple sclerosis: frequency, location, and clinical correlation. Neuroreport2000 ; 11: 15—21.
38.
Bakshi R., Benedict RH, Bermel RA, Caruthers SD, Puli SR, Tjoa CW et al. T2 hypointensity in the deep gray matter of patients with multiple sclerosis: a quantitative magnetic resonance imaging study. Arch Neurol2002; 59: 62—68.
39.
Bakshi R., Dmochowski J., Shaikh ZA, Jacobs L.Gray matter T2 hypointensity is related to plaques and atrophy in the brains of multiple sclerosis patients. J Neurol Sci2001; 185: 19—26.
40.
Peterson JW , Bo L., Mork S., Chang A., Trapp BDTransected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol2001; 50: 389—400.
41.
Fredenburg AM, Sethi RK, Allen DD, Yokel RAThe pharmacokinetics and blood-brain barrier permeation of the chelators 1,2 dimethly-, 1,2 diethyl-, and 1-[ethan-1'ol]-2-methyl-3-hydroxypyridin-4-one in the rat. Toxicology1996; 108: 191—99.
42.
Traugott U. , Raine CS, McFarlin DEAcute experimental allergic encephalomyelitis in the mouse: immunopathology of the developing lesion. Cell Immunol1985; 91: 240—54.
43.
Goldmuntz EA , Brosnan CF, Norton WTPrazosin treatment suppresses increased vascular permeability in both acute and passively transferred experimental autoimmune encephalomyelitis in the Lewis rat. J Immunol1986; 137: 3444—50.
44.
Sobel RA, Mitchell MEFibronectin in multiple sclerosis lesions. Am J Pathol1989; 135: 161—68.
45.
Rovaris M., Rodegher M., Comi G., Filippi M.Correlation between MRI and short-term clinical activity in multiple sclerosis: comparison between standard-and triple-dose Gd-enhanced MRI. Eur Neurol1999; 41: 123—27.
46.
Tortorella C., Codella M., Rocca MA, Gasperini C., Capra R., Bastianello S. et al. Disease activity in multiple sclerosis studied by weekly triple-dose magnetic resonance imaging. J Neurol1999; 246: 689—92.
47.
Silver NC, Good CD, Sormani MP, MacManus DG, Thompson AJ, Filippi M. et al. A modified protocol to improve the detection of enhancing brain and spinal cord lesions in multiple sclerosis. J Neurol2001; 248: 215—24.
48.
Silver NC, Tofts PS, Symms MR, Barker GJ, Thompson AJ, Miller DHQuantitative contrast-enhanced magnetic resonance imaging to evaluate blood-brain barrier integrity in multiple sclerosis: a preliminary study. Mult Scler2001; 7: 75—82.
49.
Richardson DRNovel chelators for central nervous system disorders that involve alterations in the metabolism of iron and other metal ions. Ann N Y Acad Sci2004; 1012: 326—41.
50.
van derKraaij AM, van Eijk HG, Koster JFPrevention of postischemic cardiac injury by the orally active iron chelator 1,2-dimethyl-3-hydroxy-4-pyridone (L1) and the antioxidant (+)-cyanidanol-3 . Circulation1989; 80: 158—64.
51.
Chenoufi N. , Hubert N., Loreal O., Morel I., Pasdeloup N., Cillard J. et al. Inhibition of iron toxicity in rat and human hepatocyte cultures by the hydroxypyridin-4-ones CP20 and CP94. J Hepatol1995; 23: 166—73.
Whitley WD, Hancock WW, Kupiec-Weglinski JW, DeSousa M., Tilney NLIron chelation suppresses mononuclear cell activation, modifies lymphocyte migration patterns, and prolongs rat cardiac allograft survival in rats. Transplantation1993; 56: 1182—88.
54.
Lederman HM , Cohen A., Lee JW, Freedman MH, Gelfand EWDeferoxamine: a reversible S-phase inhibitor of human lymphocyte proliferation. Blood1984 ; 64: 748—53.
55.
Leung S., Holbrook A., King B., Lu HT, Evans V., Miyamoto N. et al. Differential inhibition of inducible T cell cytokine secretion by potent iron chelators. J Biomol Screen2005; 10: 157—67.
56.
Hileti D., Panayiotidis P., Hoffbrand AVIron chelators induce apoptosis in proliferating cells. Br J Haematol1995; 89: 181—87.
57.
Matsui D., Klein J., Hermann C., Grunau V., McClelland R., Chung D. et al. Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassemia. Clin Pharmacol Ther1991; 50: 294—98.
58.
Thuma PE, Olivieri NF, Mabeza GF, Biemba G., Parry D., Zulu S. et al. Assessment of the effect of the oral iron chelator deferiprone on asymptomatic Plasmodium falciparum parasitemia in humans. Am J Trop Med Hyg1998; 58: 358—64.
59.
Cohen A., Galanello R., Piga A., Vullo C., Tricta F.A multi-center safety trial of the oral iron chelator deferiprone. Ann N Y Acad Sci1998; 850: 223—26.
60.
Omara FO, Blakley BRThe effects of iron deficiency and iron overload on cell-mediated immunity in the mouse. Br J Nutr1994; 72: 899—909.
61.
Grant SM, Wiesinger JA, Beard JL, Cantorna MTIron-deficient mice fail to develop autoimmune encephalomyelitis. J Nutr2003; 133: 2635—38.
62.
Bitsch A., Schuchardt J., Bunkowski S., Kuhlmann T., Bruck W.Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain2000; 123: 1174—83.
63.
Kutzelnigg A., Lassmann H.Cortical lesions and brain atrophy in MS. J Neurol Sci2005; 233: 55—59.
64.
Tedeschi G. , Lavorgna L., Russo P., Prinster A., Dinacci D., Savettieri G. et al. Brain atrophy and lesion load in a large population of patients with multiple sclerosis. Neurology2005; 65: 280—85.
65.
Rovaris M., Confavreux C., Furlan R., Kappos L., Comi G., Filippi M.Secondary progressive multiple sclerosis: current knowledge and future challenges . Lancet Neurol2006; 5: 343—54.
66.
Bartnik BL, Juurlink BH, Devon RMMacrophages: their myelinotrophic or neurotoxic actions depend upon tissue oxidative stress. Mult Scler2000; 6: 37—42.
67.
Penkowa M., Espejo C., Martinez-Caceres EM, Montalban X., Hidalgo J.Increased demyelination and axonal damage in metallothionein I+II-deficient mice during experimental autoimmune encephalomyelitis. Cell Mol Life Sci2003; 60: 185—97.
68.
Roediger B. , Armati PJOxidative stress induces axonal beading in cultured human brain tissue. Neurobiol Dis2003; 13: 222—29.
69.
Bizzozero OA , DeJesus G., Callahan K., Pastuszyn A.Elevated protein carbonylation in the brain white matter and gray matter of patients with multiple sclerosis. J Neurosci Res2005; 81: 687—95.
70.
Exley C., Mamutse G., Korchazhkina O., Pye E., Strekopytov S., Polwart A. et al. Elevated urinary excretion of aluminium and iron in multiple sclerosis. Mult Scler2006; 12: 533—40.
71.
LeVine SM, Lynch SG, Ou CN, Wulser MJ, Tam E., Boo N.Ferritin, transferrin and iron concentrations in the cerebrospinal fluid of multiple sclerosis patients. Brain Res1999 ; 821: 511—15.
72.
Petzold A., Eikelenboom MJ, Gveric D., Keir G., Chapman M., Lazeron RH et al. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain2002; 125: 1462—73.
73.
Sfagos C., Makis AC, Chaidos A., Hatzimichael EC, Dalamaga A., Kosma K. et al. Serum ferritin, transferrin and soluble transferrin receptor levels in multiple sclerosis patients. Mult Scler2005; 11: 272—75.
74.
Neufeld EJOral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood2006; 107: 3436—41 (review).
75.
Zamboni P.The big idea: iron-dependent inflammation in venous disease and proposed parallels in multiple sclerosis. J R Soc Med2006; 99: 589—93.
